304
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Endogenous Bacterial Endophthalmitis: A Five-Year Retrospective Review at a Tertiary Care Academic Center

, MD, , MD, , MD, , MD, , MD, MPH, & , MD, FACS show all
Pages 975-983 | Received 16 Mar 2019, Accepted 08 Jul 2019, Published online: 16 Aug 2019
 

ABSTRACT

Purpose

To better characterize the demographics and outcomes of endogenous bacterial endophthalmitis (EBE).

Methods

Retrospective observational case series of 49 eyes of 41 patients with EBE evaluated at a single academic center.

Results

Gram stain (p = .395), symptom duration prior to treatment (p = .483), and number of intravitreal antimicrobial injections (p = .421) did not correlate with mean change in VA. There was no significant difference between mean LogMAR VA at initial evaluation (1.7 ± 0.9) and last available follow up (1.4 ± 1.1, p = .15). Patients with bilateral EBE had 7.25 times greater odds of having cancer (95% CI 1.28, 41.14; p = .025).

Conclusion

EBE in a North American population showed poor visual recovery despite treatment. It was most commonly due to gram-positive bacteria with the most common infectious source being endocarditis. Malignancy should be considered in patients with bilateral EBE.

Declaration of interest

No conflicting relationships, competing interests or funding in relation to this study exist for any author.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.